Drug intelligence / Profile preview

esomeprazole + sildenafil citrate

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Esomeprazole + sildenafil citrate is a combination of two small molecule drugs, each with distinct mechanisms of action and clinical indications. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the (H+, K+)-ATPase enzyme in gastric parietal cells, leading to reduced stomach acidity. It is primarily used for gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication regimens, prevention of NSAID-induced gastrointestinal injury, and other acid-related disorders[2][8]. Sildenafil citrate is a phosphodiesterase-5 (PDE5) inhibitor that increases cyclic GMP levels by inhibiting PDE5 in smooth muscle tissue; this results in vasodilation and increased blood flow. Sildenafil's main indications are erectile dysfunction and pulmonary arterial hypertension[4][6]. There are no known clinically significant interactions between these two drugs when co-administered[1][3].

Other names
esomeprazole and sildenafil citrateesomeprazole + sildenafil
02

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on esomeprazole + sildenafil citrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on esomeprazole + sildenafil citrate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call